Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + topotecan
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A chemotherapy combination regimen consisting of gemcitabine and topotecan administered intravenously. This combination has been studied primarily for the treatment of recurrent ovarian cancer, particularly in patients who have relapsed after platinum/taxane-based first-line chemotherapy. It has shown modest activity with manageable toxicity profiles, even in heavily pretreated patients.
- Brand names
- HycamtinGemzar
- Other names
- gemcitabine + topotecantopotecan and gemcitabinegemcitabine and topotecan
02
Targets
TOP1 (DNA Topoisomerase I)DNA polymerase family
Beyond the preview
Go deeper on gemcitabine + topotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + topotecan.